Latest News - Clinical Trials

Monday, May 15, 2017 | Clinical Trials, Glaucoma

Isarna Presents Positive Clinical Data for ISTH0036 in Advanced Glaucoma and Preclinical Data Supportive of AMD/DME Potential at ARVO

Isarna Therapeutics announced the presentation of the phase I safety and efficacy data for its lead candidate ISTH0036, a locked nucleic acid-modified antisense oligonucleotide, in advanced-stage glau…

Read the full story

Monday, May 15, 2017 | Clinical Trials, Glaucoma, Aerie Pharmaceuticals

Aerie Pharmaceuticals Announces FDA Acceptance of NDA Submission for Rhopressa

Aerie Pharmaceuticals reported that it has received notification from the FDA that the agency has completed its initial 60-day review of the Rhopressa new drug application (NDA) and determined that th…

Read the full story

Friday, May 12, 2017 | Clinical Trials

Pharmaleads Reports Positive Ocular Pain Results with PL265, a Novel Dual Enkephalinase Inhibitor (DENKI) at ARVO

Pharmaleads announced positive efficacy and safety results of PL265, a novel Dual ENKephalinase Inhibitor (DENKI), in a preclinical study for ocular pain. This study was conducted in collaboration wit…

Read the full story

Wednesday, May 10, 2017 | Clinical Trials, BioTime

BioTime Announces New Positive Data from OpRegen Trial in Dry-AMD

BioTime announced new data from the phase 1/2a clinical trial of OpRegen in the advanced form of dry age-related macular degeneration (AMD). The interim data were presented on May 8, 2017 at the …

Read the full story

Wednesday, May 10, 2017 | Clinical Trials, Ocular Therapeutix

Ocular Therapeutix Presents Preclinical Data on Pharmacokinetics, Efficacy and Tolerability of Sustained-Release Intravitreal Tyrosine Kinase Inhibitor Hydrogel Depot (OTX-TKI)

Ocular Therapeutix presented data from preclinical studies evaluating the efficacy, tolerability, and pharmacokinetics of its sustained-release intravitreal tyrosine kinase inhibitor (TKI) depot (OTX-…

Read the full story

Tuesday, May 09, 2017 | Clinical Trials, Bausch+Lomb, Valeant

Bausch + Lomb Announces PDUFA Date For Luminesse

Bausch + Lomb announced that the FDA accepted the new drug application (NDA) for brimonidine tartrate ophthalmic solution, 0.025% (Luminesse), and set a PDUFA action date of December 27, 2017. Lumines…

Read the full story

Tuesday, May 09, 2017 | Clinical Trials

Eyevensys Announces the First-in-Human Treatment with its EyeCET ElectroTransfection Technology for Eye Diseases

Eyevensys announced that it has successfully treated the first patient in a first-in-human phase 1/2 trial of its lead candidate EYS606 for non-infectious uveitis (NIU). The patient was treated in Par…

Read the full story

Monday, May 08, 2017 | Clinical Trials, Ocular Therapeutix

Ocular Therapeutix Presents Additional Phase 3 Data and Patient Reported Outcomes Results for Dextenza at ASCRS

Ocular Therapeutix presented new data from its most recent phase 3 study evaluating the safety and efficacy of Dextenza (dexamethasone insert) 0.4 mg for the treatment of ocular pain and inflammation …

Read the full story

Thursday, May 04, 2017 | Clinical Trials

Refocus Group Concludes 12-Month Follow-Up for Phase 3 Clinical Trial on the VisAbility Micro-Insert System for Presbyopia

Refocus Group announced that it has successfully completed its 12-month follow-up on 360 patients in its pivotal trial of the VisAbility Micro-Insert System for presbyopia. The announcement paves the …

Read the full story

Thursday, May 04, 2017 | Clinical Trials, Eyegate Pharmaceuticals

EyeGate Submits IDE Filing for Second Pilot Study of Ocular Bandage Gel

EyeGate Pharmaceuticals announced that it has submitted an investigational device exemption (IDE) for the lead product in its cross-linked thiolated carboxymethyl hyaluronic acid (CMHA-S) platform, Ey…

Read the full story

Wednesday, May 03, 2017 | Clinical Trials, Glaukos Corporation

Glaukos Completes Patient Enrollment in Phase II Clinical Trial for iDose Travoprost Intraocular Implant in Glaucoma Patients

Glaukos Corporation announced the completion of patient enrollment in the investigational new drug (IND) phase 2 study of its Travoprost intraocular implant with the iDose delivery system in patients …

Read the full story

Monday, May 01, 2017 | Clinical Trials, Kala Pharmaceuticals

Kala Pharmaceuticals Announces Positive Results from Confirmatory Phase 3 Trial of KPI-121 1% Following Cataract Surgery

Kala Pharmaceuticals announced positive topline results from its confirmatory phase 3 trial of KPI-121 1% for the treatment of inflammation and pain in patients who have undergone cataract surgery. KP…

Read the full story

Tuesday, April 25, 2017 | Clinical Trials, Santen

FDA Accepts Santen's NDA for Intravitreal Sirolimus in the Treatment of Noninfectious Uveitis of the Posterior Segment

Santen Pharmaceutical announced that the FDA has accepted for review the new drug application (NDA) for intravitreal sirolimus (440 µg), development code DE-109, for the treatment of noninfectio…

Read the full story

Monday, April 24, 2017 | Clinical Trials, Shire

Shire Initiates Phase 3 Clinical Trial Program for SHP640 in Infectious Conjunctivitis for Adults and Children

Shire announced the initiation of the phase 3 clinical development program for SHP640, a combination broad spectrum antiseptic and corticosteroid in development for the treatment of infectious conjunc…

Read the full story

Monday, April 24, 2017 | Clinical Trials, Ocular Therapeutix

Ocular Therapeutix to Present Additional Phase 3 Data and Patient Reported Outcomes Results for Dextenza at ASCRS

Ocular Therapeutix announced new data to be presented from its most recent phase 3 study evaluating the efficacy and safety of Dextenza (dexamethasone insert, 0.4mg) for intracanalicular use for the t…

Read the full story
Load More